Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 3/2019

01-05-2019 | Radiotherapy | Clinical Study

Proton therapy for skull-base chondrosarcoma, a single-institution outcomes study

Authors: Adam L. Holtzman, Ronny L. Rotondo, Michael S. Rutenberg, Daniel J. Indelicato, Catherine E. Mercado, Dinesh Rao, Daryoush Tavanaiepour, Christopher G. Morris, Debbie Louis, Stella Flampouri, William M. Mendenhall

Published in: Journal of Neuro-Oncology | Issue 3/2019

Login to get access

Abstract

Background

We sought to evaluate the effectiveness of definitive or adjuvant external-beam proton therapy on local control and survival in patients with skull-base chondrosarcoma.

Methods

We reviewed the medical records of 43 patients with a median age of 49 years (range, 23–80 years) treated with double-scattered 3D conformal proton therapy for skull-base chondrosarcomas between January 2007 and February 2016. Proton therapy-related toxicities were scored using CTCAE v4.0.

Results

The median radiotherapy dose was 73.8 Gy(RBE) (range, 64.5–74.4 Gy[RBE]). Thirty-six (84%) and 7 (16%) patients underwent surgical resection or biopsy alone. Tumor grade distribution included: grade 1, 19 (44%) patients; grade 2, 22 (51%); and grade 3, 2 (5%). Forty patients had gross disease at the time of radiotherapy and 7 patients were treated for locally recurrent disease following surgery. The median follow-up was 3.7 years (range, 0.7–10.1 years). There were no acute grade 3 toxicities related to RT. At 4 years following RT, actuarial rates of overall survival, cause-specific survival, local control, and RT-related grade 3 toxicity-free survival were 95%, 100%, 89%, and 95%.

Conclusion

High-dose, double-scattered 3D conformal proton therapy alone or following surgical resection for skull-base chondrosarcoma is an effective treatment with a high rate of local control with no acute grade 3 radiation-related toxicity. Further follow-up of this cohort is necessary to better characterize long-term disease control and late toxicities.
Literature
1.
Harsh GR, Vaz-Guimaraes F (eds) (2017) Chordomas and chondrosarcomas of the skull base and spine, 2nd edn. Academic Press, Cambridge, MA
2.
Fossati P, Vavassori A, Deantonio L, Ferrara E, Krengli M, Orecchia R (2016) Review of photon and proton radiotherapy for skull base tumours. Rep Pract Oncol Radiother 21(4):336–355CrossRef
3.
Sahgal A, Chan MW, Atenafu EG, Masson-Cote L, Bahl G, Yu E et al (2015) Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and chondrosarcoma: preliminary outcomes. Neuro-Oncology 17(6):889–894CrossRef
4.
Palm RF, Oliver DE, Yang GQ, Abuodeh Y, Naghavi AO, Johnstone PAS (2019) The role of dose escalation and proton therapy in perioperative or definitive treatment of chondrosarcoma and chordoma: an analysis of the National Cancer Data Base. Cancer 125(4):642–651CrossRef
5.
Verdegaal SH, Bovee JV, Pansuriya TC, Grimer RJ, Ozger H, Jutte PC et al (2011) Incidence, predictive factors, and prognosis of chondrosarcoma in patients with ollier disease and maffucci syndrome: an international multicenter study of 161 patients. Oncologist 16(12):1771–1779CrossRef
6.
Deraniyagala RL, Yeung D, Mendenhall WM, Li Z, Morris CG, Mendenhall NP et al (2014) Proton therapy for skull base chordomas: an outcome study from the university of Florida proton therapy institute. J Neurol Surg B 75(1):53–57CrossRef
7.
Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH et al (2008) The clinical approach towards chondrosarcoma. Oncologist 13(3):320–329CrossRef
8.
Bloch OG, Jian BJ, Yang I, Han SJ, Aranda D, Ahn BJ et al (2010) Cranial chondrosarcoma and recurrence. Skull Base 20(3):149–156CrossRef
9.
Tzortzidis F, Elahi F, Wright DC, Temkin N, Natarajan SK, Sekhar LN (2006) Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chondrosarcomas. Neurosurgery 58(6):1090–1098CrossRef
10.
Gay E, Sekhar LN, Rubinstein E, Wright DC, Sen C, Janecka IP et al (1995) Chordomas and chondrosarcomas of the cranial base: results and follow-up of 60 patients. Neurosurgery 36(5):887–896.CrossRef
11.
Rosenberg AE, Nielsen GP, Keel SB, Renard LG, Fitzek MM, Munzenrider JE et al (1999) Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma. Am J Surg Pathol 23(11):1370–1378CrossRef
12.
Ares C, Hug EB, Lomax AJ, Bolsi A, Timmermann B, Rutz HP et al (2009) Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. Int J Radiat Oncol, Biol, Phys 75(4):1111–1118CrossRef
13.
Feuvret L, Bracci S, Calugaru V, Bolle S, Mammar H, De Marzi L et al (2016) Efficacy and safety of adjuvant proton therapy combined with surgery for chondrosarcoma of the skull base: a retrospective, population-based study. Int J Radiat Oncol, Biol, Phys 95(1):312–321CrossRef
14.
Fuji H, Nakasu Y, Ishida Y, Horiguchi S, Mitsuya K, Kashiwagi H et al (2011) Feasibility of proton beam therapy for chordoma and chondrosarcoma of the skull base. Skull Base 21(3):201–206CrossRef
15.
Hug EB, Loredo LN, Slater JD, DeVries A, Grove RI, Schaefer RA et al (1999) Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg 91(3):432–439CrossRef
16.
Weber DC, Murray F, Combescure C, Calugaru V, Alapetite C, Albertini F et al (2018) Long term outcome of skull-base chondrosarcoma patients treated with high-dose proton therapy with or without conventional radiation therapy. Radiother Oncol 129:520–526CrossRef
17.
Weber DC, Malyapa R, Albertini F, Bolsi A, Kliebsch U, Walser M et al (2016) Long term outcomes of patients with skull-base low-grade chondrosarcoma and chordoma patients treated with pencil beam scanning proton therapy. Radiother Oncol 120(1):169–174CrossRef
18.
Munzenrider JE, Liebsch NJ (1999) Proton therapy for tumors of the skull base. Strahlentherapie und Onkologie 175(Suppl 2):57–63CrossRef
19.
Grosshans DR, Zhu XR, Melancon A, Allen PK, Poenisch F, Palmer M et al (2014) Spot scanning proton therapy for malignancies of the base of skull: treatment planning, acute toxicities, and preliminary clinical outcomes. Int J Radiat Oncol, Biol, Phys 90(3):540–546CrossRef
20.
Mattke M, Vogt K, Bougatf N, Welzel T, Oelmann-Avendano J, Hauswald H et al (2018) High control rates of proton- and carbon-ion-beam treatment with intensity-modulated active raster scanning in 101 patients with skull base chondrosarcoma at the Heidelberg Ion Beam Therapy Center. Cancer 124(9):2036–2044CrossRef
21.
Uhl M, Mattke M, Welzel T, Oelmann J, Habl G, Jensen AD et al (2014) High control rate in patients with chondrosarcoma of the skull base after carbon ion therapy: first report of long-term results. Cancer 120(10):1579–1585CrossRef
22.
Li D, Weng JC, Zhang GJ, Hao SY, Tang J, Zhang LW et al (2018) Proposed treatment paradigm for intracranial chondrosarcomas based on multidisciplinary coordination. World Neurosurg 109:e517–e530CrossRef
23.
Bohman LE, Koch M, Bailey RL, Alonso-Basanta M, Lee JY (2014) Skull base chordoma and chondrosarcoma: influence of clinical and demographic factors on prognosis: a SEER analysis. World Neurosurg 82(5):806–814CrossRef
24.
Uhl M, Herfarth K, Debus J (2014) Comparing the use of protons and carbon ions for treatment. Cancer J (Sudbury, Mass). 20(6):433–439CrossRef
25.
Combs SE, Nikoghosyan A, Jaekel O, Karger CP, Haberer T, Munter MW et al (2009) Carbon ion radiotherapy for pediatric patients and young adults treated for tumors of the skull base. Cancer 115(6):1348–1355CrossRef
26.
Schulz-Ertner D, Nikoghosyan A, Hof H, Didinger B, Combs SE, Jakel O et al (2007) Carbon ion radiotherapy of skull base chondrosarcomas. Int J Radiat Oncol, Biol, Phys 67(1):171–177CrossRef
27.
Rieken S, Habermehl D, Nikoghosyan A, Jensen A, Haberer T, Jakel O et al (2011) Assessment of early toxicity and response in patients treated with proton and carbon ion therapy at the Heidelberg ion therapy center using the raster scanning technique. Int J Radiat Oncol, Biol, Phys 81(5):e793–e801CrossRef
28.
Terezakis SA, Heron DE, Lavigne RF, Diehn M, Loo BW (2011) Jr. What the diagnostic radiologist needs to know about radiation oncology. Radiology 261(1):30–44CrossRef
29.
Ballo MT, Chronowski GM, Schlembach PJ, Bloom ES, Arzu IY, Kuban DA (2014) Prospective peer review quality assurance for outpatient radiation therapy. Pract Radiat Oncol 4(5):279–284CrossRef
30.
Li CS, Vannabouathong C, Sprague S, Bhandari M (2015) The use of carbon-fiber-reinforced (CFR) PEEK material in orthopedic implants: a systematic review. Clin Med Insights Arth Musculoskelet Disord 8:33–45
31.
Frezza AM, Cesari M, Baumhoer D, Biau D, Bielack S, Campanacci DA et al (2015) Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European musculoskeletal oncology society study. Eur J Cancer (Oxford, England: 1990) 51(3):374–381CrossRef
32.
van Maldegem A, Conley AP, Rutkowski P, Patel SR, Lugowska I, Desar IME et al (2018) Outcome of first-line systemic treatment for unresectable conventional, dedifferentiated, mesenchymal, and clear cell chondrosarcoma. Oncologist 24:110–116CrossRef
Metadata
Title
Proton therapy for skull-base chondrosarcoma, a single-institution outcomes study
Authors
Adam L. Holtzman
Ronny L. Rotondo
Michael S. Rutenberg
Daniel J. Indelicato
Catherine E. Mercado
Dinesh Rao
Daryoush Tavanaiepour
Christopher G. Morris
Debbie Louis
Stella Flampouri
William M. Mendenhall
Publication date
01-05-2019
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 3/2019
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-019-03129-8

Other articles of this Issue 3/2019

Journal of Neuro-Oncology 3/2019 Go to the issue

Laboratory Investigation

Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood

Clinical Study

Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma

Clinical Study

Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases

Clinical Study

High-dose radiation therapy is needed for intracranial control and long-term survival in patients with non-seminomatous germ cell tumor brain metastases

Clinical Study

Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD)

Clinical Study

Trans-eyebrow supraorbital keyhole approach to tuberculum sellae meningiomas: a series of 30 cases with long-term visual outcomes and recurrence rates